New stock news | Genesee Bio submits application to Hong Kong Stock Exchange Main Board

According to the disclosure of the Hong Kong Stock Exchange on December 10th, Shanghai Jinyu Bio-Technology Co., Ltd. (Jinyu Bio-Technology) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its sole sponsor. The prospectus shows that Jinyu Bio-Technology is a biotechnology company dedicated to the innovation of solid tumor cell therapy and innovative drug development, focusing on the development of safer, more effective, more accessible, and more affordable immunocellular therapies that are not constrained by any fixed molecular targets, covering the most common or most difficult-to-treat solid tumors. According to Frost & Sullivan data, the company's core product GC101 is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity ablative chemotherapy or IL-2 administration, and is expected to become China's first approved TIL therapy to be listed on the market.